Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

Also called NCT05795517

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 210 participants (enrolled count) (from the registry)
Sponsor
Haisco Pharmaceutical Group Co., Ltd. (from the registry)
Registry
  • NCT NCT05795517
Other papers using this trial's data
  • Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026-04 DOI, PubMed 40846146

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05795517. Randomized; double masking; primary purpose treatment. Start 2023-04-26 (actual); primary completion 2024-02-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)
Condition
Hypercholesterolemia
Intervention (Drug)
HSK31679 low dose
Intervention (Drug)
HSK31679 medium dose
Intervention (Drug)
HSK31679 high dose
Intervention (Drug)
Placebo
Intervention (Drug)
Ezetimibe 10mg
Lead sponsor
Haisco Pharmaceutical Group Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05795517
Content hash
f029eaa7771753d66cc6a9728f18a7e18743d8502e9fd0fb23baefd35d5f44b5